Tarka Related Published Studies
Well-designed clinical trials related to Tarka (Trandolapril / Verapamil)
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. [2001.01]
Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. [2000.06]
Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. [2000]
Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. [1999.05]
Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. [1999.01]
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. [1998.11]
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. [1998.08]
Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group. [1998.05]
Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. [1998.03]
Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. [1998.01]
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. [1997.08]
Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. [1997.07]
Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group. [1997.04]
Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. [1997.03.15]
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. [1996.05]
Well-designed clinical trials possibly related to Tarka (Trandolapril / Verapamil)
Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. [2008.07]
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. [2008.01]
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. [2006.12]
Controlled-release carvedilol in the treatment of essential hypertension. [2006.10.02]
Preventing microalbuminuria in type 2 diabetes. [2004.11.04]
Characteristics of contemporary patients with hypertension and coronary artery disease. [2004.10]
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResion Arterial en DIabeticos tipo Dos) study. [2004.01]
Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. [2002.12]
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study] [2002]
Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. [2001.12]
Renal adaptive mechanisms in aged and hypertensive humans: possible effects of treatment. [2001.11]
Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension. [2001.10]
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. [2001]
Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. [2000.09]
Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. [1999.12]
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. [1998.10]
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. [1998.01]
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. [1997.01]
Other research related to Tarka (Trandolapril / Verapamil)
Trandolapril/verapamil combination in hypertensive diabetic patients. [2007]
Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. [2007]
Trandolapril/verapamil combination in hypertensive diabetic patients. [2007]
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). [2005.05]
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. [2005]
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. [2004.11]
Trandolapril: a newer angiotensin-converting enzyme inhibitor. [2003.03]
Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study. [2003.01]
[Treatment of hypertension in diabetics with trandolapril, an angiotensin converting enzyme inhibitor--a multicenter study] [2002.08]
Beneficial effects of trandolapril in uninephrectomized spontaneously hypertensive rats: role of cyclooxygenase pathway. [2002.08]
High-dose verapamil + trandolapril-induced thrombotic microangiopathy. [2002]
Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. [2002]
[The effect of trandolapril, in monotherapy and associated with verapamil, on arterial pressure, albuminuria, and metabolic control in hypertensive patients with type 2 diabetes and albuminuria] [2001.09]
Verapamil SR and trandolapril combination therapy is safe and effective in hypertensive patients with metabolic disorders. [2001.01]
The fixed combination of verapamil SR/trandolapril. [2000.03]
Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension. [1999.05]
Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. [1999.01]
Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. [1998.11.13]
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. [1998.11]
Fixed combination verapamil SR/trandolapril. [1998.11]
Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment. [1998.10]
Antihypertensive action of trandolapril and verapamil in spontaneously hypertensive rats after unilateral nephrectomy. [1998.08]
[The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil] [1998.06]
The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. [1997.08]
Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. [1997.03.15]
Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). [1997.03]
Safety profile of the combination of verapamil and trandolapril. [1997.03]
Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. [1997.03]
Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment. [1997.02]
Trandolapril plus verapamil inhibits the coronary vasospasm induced by hypoxia following ischemia-reperfusion injury in dogs. [1996.09]
Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination. [1996.07.05]
Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. [1996.05]
Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. [1996.01]
L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. [1995.11]
Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. [1994.12]
Other possibly related research studies
Chronic toxicity/carcinogenicity studies of cocoa powder in rats. [1991.01]
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. [2005.11]
Therapeutic controversies in hypertension. [2005.07]
[Concomitant use of statins and cytochrome P 450 inhibitors in Croatia] [2005.03]
Improving control of hypertension by an integrated approach -- results of the 'Manage it well!' programme. [2005.01]
[Lethal polypharmacy in a patient with arterial hypertension] [2004.12.10]
Calcium channel blockers: an update. [2004.01.01]
Verapamil reverts acute renal functional impairment induced by angiotensin II converting enzyme inhibitors. [2003.09]
Some recent randomized clinical trials in the management of atrial fibrillation. [2003.10]
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure] [2002.11.09]
Verapamil revisited: a transition in novel drug delivery systems and outcomes. [2001.01]
Characteristics of patients with coronary artery disease and hypertension: a report from INVEST. [2001.11]
How will INVEST and other hypertension trials change clinical practice? [2001.11]
Enhancing clinical trials on the internet: lessons from INVEST. [2001.11]
Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. [2001.11]
INVEST: results of combined strategies to control blood pressure. [2001.11]
The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. [2001.11]
[Diabetic nephropathy with nephrotic syndrome--apropos of 2 cases. Advantages of combined conversion enzyme inhibitor and non-dihydropyridine calcium antagonist treatment] [2000.08.24]
The effects of anti-hypertensive therapy on the structural, mechanical and metabolic properties of the rat aorta. [2000.04]
How can hypertensive patients be better treated? The contribution of combination therapy. [2000]
Mesenteric cyclooxygenase products after combined antihypertensive treatment in uninephrectomized SHRs. [2000.02]
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy] [1999]
[Antihypertensive therapy in diabetes mellitus] [1999.01]
Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. [1998.04]
Combination of ACE inhibitors and calcium antagonists: a logical approach. [1998]
Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. [1998.01]
Renal effects of antihypertensive therapy in uninephrectomized diabetic rats. [1997]
Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? [1997.08]
|
